



(51) International Patent Classification:

A61K 39/395 (2006.01) A61K 39/00 (2006.01)
C07K 16/22 (2006.01)

(21) International Application Number:

PCT/US2017/063417

(22) International Filing Date:

28 November 2017 (28.11.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/427,365 29 November 2016 (29.11.2016) US

(71) Applicant: REGENERON PHARMACEUTICALS, INC. [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: STEHMAN-BREEN, Catherine; 5 Meeting-house Lane, York, Maine 03909 (US). DAVIS, John; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: BOZICEVIC, Karl; c/o Bozicevic Field & Francis LLP, 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94065 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: A PHARMACEUTICAL COMPOSITION FOR AVERTING OPIOID ADDICTION




FIG. 4

(57) Abstract: A pharmaceutical composition for averting opioid addiction in a patient is disclosed. The composition can be used in a patient suffering from moderate to severe low back pain (LBP). The composition is useful in a patient diagnosed with low back pain, and comprises a therapeutically effective amount of an antibody that binds specifically to nerve growth factor (NGF) or an antigen binding fragment thereof; and is used in the absence of an opioid to relieve pain, and avert opioid addiction in a patient.

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))